Literature DB >> 12955295

Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.

Richard Ian Dafters1, Rosa Hoshi, Annie Claire Talbot.   

Abstract

RATIONALE: Establishing whether cognitive changes follow long-term use of MDMA ("ecstasy") in humans has been difficult because of possible confounds with other drug use, particularly cannabis. Convincing evidence may be only obtained using experimental designs that account for such confounds.
OBJECTIVE: In the present study, cognitive/behavioural measures were used to investigate whether long-term MDMA use or long-term cannabis use is responsible for the changes sometimes observed in recreational MDMA users.
METHOD: Tests of attention and memory were administered to subjects who used both MDMA and cannabis, cannabis only, or neither drug.
RESULTS: The main finding was that cannabis users, whether or not they also used MDMA, showed significantly impaired memory function on word free-recall and on immediate and delayed story recall compared to non-users.
CONCLUSIONS: The findings highlight the importance of controlling for other drug use (particularly cannabis) when investigating persistent effects of MDMA in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955295     DOI: 10.1007/s00213-003-1561-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Auditory verbal learning in drug-free Ecstasy polydrug users.

Authors:  H. C. Fox; A. S. Toplis; J. J. D. Turner; A. C. Parrott
Journal:  Hum Psychopharmacol       Date:  2001-12       Impact factor: 1.672

2.  The relative contributions of ecstasy and cannabis to cognitive impairment.

Authors:  R J Croft; A J Mackay; A T Mills; J G Gruzelier
Journal:  Psychopharmacology (Berl)       Date:  2001-01       Impact factor: 4.530

3.  Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.

Authors:  H V Curran; R A Travill
Journal:  Addiction       Date:  1997-07       Impact factor: 6.526

4.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

5.  Effects of chronic marijuana use on human cognition.

Authors:  R I Block; M M Ghoneim
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test.

Authors:  H E Nelson; A O'Connell
Journal:  Cortex       Date:  1978-06       Impact factor: 4.027

Review 7.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.

Authors:  G A Ricaurte; J Yuan; U D McCann
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

8.  Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity.

Authors:  M J Morgan
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

9.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.

Authors:  A C Parrott; J Lasky
Journal:  Psychopharmacology (Berl)       Date:  1998-10       Impact factor: 4.530

View more
  16 in total

1.  Reasoning deficits in ecstasy (MDMA) polydrug users.

Authors:  John E Fisk; Catharine Montgomery; Michelle Wareing; Philip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

2.  Is there a role for marijuana in medical practice?

Authors:  Mark A Ware; Meldon Kahan; Anita Srivastava
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

3.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2008-07-27       Impact factor: 4.530

4.  Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected.

Authors:  Kim P C Kuypers; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2006-03-01       Impact factor: 4.530

5.  The nature of ecstasy-group related deficits in associative learning.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

6.  Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Authors:  Karen L Hanson; Monica Luciana; Kristin Sullwold
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

Review 7.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

8.  Functional MRI study of working memory in MDMA users.

Authors:  F Gerard Moeller; Joel L Steinberg; Donald M Dougherty; Ponnada A Narayana; Larry A Kramer; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2004-06-18       Impact factor: 4.530

9.  Effects of MDMA on olfactory memory and reversal learning in rats.

Authors:  Andrew Hawkey; L Brooke April; Mark Galizio
Journal:  Neurobiol Learn Mem       Date:  2014-07-10       Impact factor: 2.877

10.  Impaired cognition and attention in adults: pharmacological management strategies.

Authors:  Hervé Allain; Yvette Akwa; Lucette Lacomblez; Alain Lieury; Danièle Bentué-Ferrer
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.